Vertical transmission of zika virus and its outcomes:a Bayesian synthesis of prospective studies by Ades, A E et al.
                          Ades, A. E., Soriano-Arandes, A., Alarcon, A., Bonfante, F., Thorne,
C., Peckham, C., & Giaquinto, C. (2020). Vertical transmission of zika
virus and its outcomes: a Bayesian synthesis of prospective studies.
The Lancet Infectious Diseases, 0, 1-9. https://doi.org/10.1016/S1473-
3099(20)30432-1
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/S1473-3099(20)30432-1
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30432-1/fulltext#%20 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
www.thelancet.com/infection   Published online October 14, 2020    https://doi.org/10.1016/S1473-3099(20)30432-1 1
Articles
Vertical transmission of Zika virus and its outcomes: 
a Bayesian synthesis of prospective studies
A E Ades, Antoni Soriano-Arandes, Ana Alarcon, Francesco Bonfante, Claire Thorne, Catherine S Peckham, Carlo Giaquinto
Summary
Background Prospective studies of Zika virus in pregnancy have reported rates of congenital Zika syndrome and other 
adverse outcomes by trimester. However, Zika virus can infect and damage the fetus early in utero, but clear before 
delivery. The true vertical transmission rate is therefore unknown. We aimed to provide the first estimates of 
underlying vertical transmission rates and adverse outcomes due to congenital infection with Zika virus by trimester 
of exposure.
Methods This was a Bayesian latent class analysis of data from seven prospective studies of Zika virus in pregnancy. 
We estimated vertical transmission rates, rates of Zika-virus-related and non-Zika-virus-related adverse outcomes, 
and the diagnostic sensitivity of markers of congenital infection. We allowed for variation between studies in these 
parameters and used information from women in comparison groups with no PCR-confirmed infection, where 
available.
Findings The estimated mean risk of vertical transmission was 47% (95% credible interval 26 to 76) following maternal 
infection in the first trimester, 28% (15 to 46) in the second, and 25% (13 to 47) in the third. 9% (4 to 17) of deliveries 
following infections in the first trimester had symptoms consistent with congenital Zika syndrome, 3% (1 to 7) in the 
second, and 1% (0 to 3) in the third. We estimated that in infections during the first, second, and third trimester, 
respectively, 13% (2 to 27), 3% (–5 to 14), and 0% (–7 to 11) of pregnancies had adverse outcomes attributable to Zika 
virus infection. Diagnostic sensitivity of markers of congenital infection was lowest in the first trimester (42% [18 to 72]), 
but increased to 85% (51 to 99) in trimester two, and 80% (42 to 99) in trimester three. There was substantial between-
study variation in the risks of vertical transmission and congenital Zika syndrome.
Interpretation This preliminary analysis recovers the causal effects of Zika virus from disparate study designs. Higher 
transmission in the first trimester is unusual with congenital infections but accords with laboratory evidence of 
decreasing susceptibility of placental cells to infection during pregnancy.
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Introduction
The Zika virus outbreaks in Central and South America 
in 2015–16 were accompanied by a high incidence of 
congenital microcephaly.1 The outbreaks caused wide­
spread anxiety, with women in affected areas advised to 
avoid becoming pregnant, in addition to economic 
damage from adverse travel advisories. Although Zika 
virus incidence has subsided,2 quantifying the risks 
for the fetus, neonate, and child following Zika virus 
infection in pregnancy remains a priority to inform the 
public health response to future outbreaks.
Although the causal link between Zika virus and micro­
cephaly is now established,1,3 the quantitative relation ship 
remains largely unknown. For other pathogens cau sing 
congenital infections, including cytomegalovirus, Toxo­
plasma, HIV, and hepatitis C virus, this knowledge has 
been gained through prospective cohort studies. These 
studies aim to estimate two target parameters: the vertical 
transmission rate, which is the probability of congenital 
infection following a maternal infection in pregnancy, and 
the rate of adverse outcomes due to congenital infection. 
Most vertical transmission studies include a paediatric 
control group of uninfected babies born to women infected 
in pregnancy.4–7 Comparisons between the congenitally 
infected and not congenitally infected groups can then 
establish the role of congenital infection in causing adverse 
outcomes while controlling for factors associated with 
maternal infection; this con trol group is essential to study 
less specific outcomes such as preterm delivery.8 Crucially, 
recruitment of women in such studies must be prospective 
and not the result of adverse findings on fetal or newborn 
exami nation. Otherwise the vertical trans mission rate and 
the rate of sequelae are overestimated by the selective 
recruitment of pregnancies with adverse outcomes.
Zika virus presents considerable challenges because 
laboratory markers of congenital infection, although 
having reasonable analytical sensitivity, have poor diagnos­
tic sensitivity. There is evidence that fetal infection can 
cause severe damage in utero, but that the infection then 
clears, leaving no immunological trace at delivery.9 The 
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true vertical transmission rate is therefore unobserved, 
and the rate of adverse outcomes following congenital 
infection cannot be estimated. In the absence of accurate 
diagnostic tests for congenital infection, inferences about 
the causal role of Zika virus in adverse pregnancy out­
comes therefore require a second maternal control group 
of infants born to women who have not had a Zika virus 
infection during pregnancy.10
However, Zika virus poses further difficulties: although 
PCR testing in pregnancy is a highly specific indicator of 
infection, even the most intensive PCR testing protocol 
is likely to miss Zika virus infections because of the 
short duration of the PCR response, perhaps as short as 
7 days.11 Seroconversion, IgG3, or IgM testing can identify 
infection in pregnancy, but lack specificity because of 
cross­reaction with other flaviviruses, and may only 
reflect an infection that cleared before pregnancy.12 
Therefore, control groups consisting of women with a 
negative PCR test result for Zika virus, with or without 
serological evidence of infection, will comprise infected 
and uninfected women in a proportion determined by 
the diagnostic schedule, the sensitivity and specificity of 
the diagnostic tests, and the relative incidence of Zika 
virus and other flaviviruses.
This paper presents a Bayesian latent class analysis of 
the seven prospective studies available so far. Latent class 
analysis is often used when observations fall into 
unobserved (latent) categories in unknown proportions, 
for example when estimating the accuracy of diagnostic 
tests with no gold standard.13 Our results, although 
preliminary and based on imperfect data, are of scientific 
interest in their own right, and, to our knowledge, pro­
vide the first estimates of underlying vertical transmission 
rates and adverse outcomes due to congenital infection, 
by trimester of exposure.
Methods
Study identification and data extraction
We included prospective studies of women with Zika 
virus infection in pregnancy reporting adverse pregnancy 
and birth outcomes, markers of congenital infection, 
or both, based on a previous analysis and review of 
alternative designs for prospective studies of Zika virus 
in pregnancy.10 All the seven studies known to the authors 
Research in context
Evidence before this study
Although the causal link between Zika virus in pregnancy and 
microcephaly has been established, the quantitative risks to 
the fetus and neonate can only be established by prospective 
follow-up of women with Zika virus infection in pregnancy. 
We identified seven studies published before May 31, 2019, 
for inclusion in our analysis using previously published 
criteria and forward citation searches. These studies had varied 
designs, recruiting women in different ways, some including a 
comparison group of PCR-negative women, others not; some 
have reported on markers of congenital infection, some on 
adverse outcomes, and others on both.
Reported vertical transmission rates following PCR-confirmed 
Zika virus infection in pregnancy range from 9% to 35%, 
but the standard laboratory markers of congenital infection, 
IgM and PCR, have low diagnostic sensitivity: it seems that 
the virus can infect the fetus, sometimes causing profound 
damage, but clear before delivery. As a result, the true vertical 
transmission rate in utero is unknown.
Adverse clinical outcomes have been observed in 7–45% of births 
to women with Zika virus infection in pregnancy. It is not clear 
how much of this variation is due to differences in diagnostic 
protocols or in criteria for adverse outcomes, or differences in 
vertical transmission rates between populations. In the absence 
of accurate diagnostics for maternal and congenital infection, 
conventional methods cannot estimate the causal effects of 
Zika virus in pregnancy.
Added value of this study
To our knowledge, this is the first reported synthesis of 
prospective studies of Zika virus in pregnancy, based on data 
from 1602 mother–child pairs. This Bayesian latent class 
analysis synthesises data from seven published studies with 
different designs, outcome definitions, and comparison 
groups, accounting for differences in diagnostic tests and 
protocols. Although highly preliminary, the findings are of 
scientific interest: average vertical transmission rates were 
estimated to be 47% in the first trimester, 28% in the second, 
and 25% in the third. The probability of outcomes consistent 
with congenital Zika syndrome was 9%, 3%, and 1% following 
maternal infection in the first, second, and third trimester, 
respectively. Diagnostic sensitivity of markers of congenital 
infection is lowest in the first trimester (42%), increasing to 
about 85% in the second trimester and 80% in the third. 
To our knowledge, this study is the first to estimate 
vertical transmission rates and rates of adverse outcomes 
attributable to Zika virus infection, and to show how 
the key parameters of vertical transmission of Zika virus 
can be estimated.
Implications of all the available evidence
Latent class analysis can provide estimates of the vertical 
transmission rate and the risk of adverse outcomes following 
congenital infection, allowing for differences in study design 
and reporting. The finding of higher transmission rates in the 
first trimester is unusual with congenital infections, but it 
accords with laboratory studies showing that the susceptibility 
of specific placental cells to Zika virus decreases over the course 
of pregnancy.
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as of May 31, 2019, were included in the analysis. To 
be as complete as possible, we considered studies in 
a published meta­analysis14 and did forward citation 
searches based on the seven studies and those in the 
meta­analysis. This process identified three further 
studies, all of which were excluded (appendix p 2). 
Among the seven studies, there were five prospective 
studies15–19 and two retrospectively reconstructed cohort 
studies based on registers.20,21
Table 1 shows the data in the form in which they were 
analysed from each study. Some studies provided data for 
both clinical outcomes and laboratory markers,16,18,19 some 
for clinical outcomes alone,15,17,21 and one for laboratory 
markers alone.20 Two studies20,21 did not provide break­
downs by trimester of maternal infection, but external 
information on the trimester distribution was available 
and used in the analysis (see appendix p 4).
All included studies reported fetal and neonatal 
outcomes in women with confirmed (PCR­positive) 
infection in pregnancy. Four of these studies15,19–21 also 
included a group of women who tested PCR­negative for 
Zika virus; each of these groups comprised an unknown 
mixture of infected and uninfected women. In three of 
these four comparison groups, women had serological 
markers suggestive of possible infection in pregnancy, 
based on IgM testing20,21 or IgG with non­negative plaque 
reduction neutralisation testing (PRNT).19
Clinical outcomes were categorised as symptoms con­
sistent with congenital Zika syndrome, other potentially 
Zika­virus­related outcomes (OPZROs), and no symp­
toms. Regarding congenital Zika syndrome, a paediatric 
infectious disease consultant (AS­A) and a neonatologist 
(AA) applied Hoen’s criteria17 based on earlier work23 to 
fetal losses, stillbirths, and livebirth outcomes alike, 
regardless of the trimester of maternal infection. For 
studies not reporting congenital Zika syndrome, our 
classification was based on published supplementary 
material.15,16,18 Misclassification might have occurred, and 
is examined in sensitivity analyses. OPZROs comprised 
all adverse outcomes reported in the source papers, other 
than those classified as congenital Zika syndrome. These 
adverse outcomes included other neurological, auditory, 
and ophthalmological outcomes, but source papers used 
different criteria for adverse outcomes, which were not 
detailed in full. Note that OPZROs include both Zika­
virus­related and non­Zika­virus­related outcomes. Cases 
of fetal loss or stillbirth for which the clinical classification 
was undetermined or unreported were classified as 
OPZROs, but sensitivity analyses were run in which they 
were all classified as congenital Zika syndrome or all 
classified as asympto matic. Full details of the data sources 
and data from individual cases, where possible, are shown 
in the appendix (pp 1, 2).
Statistical model
We assumed that the observed data in the included 
studies were generated by the process shown 
PCR-confirmed, by trimester of 
infection
PCR-negative, by trimester of 
infection
1 2 3 Not 
reported
1 2 3 Not 
reported
Pomar et al (2018)¹⁶
CZS
LMCI present 2 3 0 ·· ·· ·· ·· ··
LMCI absent 0 0 0 ·· ·· ·· ·· ··
OPZRO
LMCI present 5 19 6 ·· ·· ·· ·· ··
LMCI absent 9 13 4 ·· ·· ·· ·· ··
No symptoms
LMCI present 9 22 10 ·· ·· ·· ·· ··
LMCI absent 43 98 48 ·· ·· ·· ·· ··
Total mother–child 
pairs
68 155 68 ·· ·· ·· ·· ··
Nogueira et al (2018)18
CZS
LMCI present 0 0 0 ·· ·· ·· ·· ··
LMCI absent 0 0 0 ·· ·· ·· ·· ··
OPZRO
LMCI present 1 2 5 ·· ·· ·· ·· ··
LMCI absent 0 2 4 ·· ·· ·· ·· ··
No symptoms
LMCI present 1 6 3 ·· ·· ·· ·· ··
LMCI absent 2 16 12 ·· ·· ·· ·· ··
Total mother–child 
pairs
4 26 24 ·· ·· ·· ·· ··
Spanish cohort (PCR-negative patients reported as having a probable MIP)*
CZS
LMCI present 0 1 0 ·· 0 0 0 ··
LMCI absent 2 0 0 ·· 0 0 0 ··
OPZRO
LMCI present 1† 0 0 ·· 0 0 0 ··
LMCI absent 0 1† 0 ·· 6 + 1† 6 7 ··
No symptoms
LMCI present 0 0 0 ·· 0 0 0 ··
LMCI absent 2 6 1 ·· 28 48 53 ··
Total mother–child 
pairs
5 8 1 ·· 35 54 60 ··
Hoen et al (2018)17
CZS 13 3 1 ·· ·· ·· ·· ··
OPZRO 11 6 5 ·· ·· ·· ·· ··
No symptoms 165 243 108 ·· ·· ·· ·· ··
Total mother–child 
pairs
189 252 114 ·· ·· ·· ·· ··
Brasil et al (2016; PCR negative patients showed no evidence of MIP)15
CZS 2 5 0 ·· 0 0 0 ··
OPZRO 4 + 5† 29 + 3† 9 + 1† ·· 3 2 1 + 1† ··
No symptoms 9 34 24 ·· 1 33 20 ··
Total mother–child 
pairs
20 71 34 ·· 4 35 22 ··
(Table 1 continues on next page)
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schematically in the figure. Women with PCR­confirmed 
infection in preg nancy transmit Zika virus to their fetus 
with probability v, and this can lead either to congenital 
Zika syndrome with probability z, or not. If there is 
congenital infection but no congenital Zika syndrome, 
the outcome might be OPZRO with probability a, or no 
symptoms with probability 1–a. Note that in fetuses with 
congenital infection, an OPZRO could either be Zika­
virus­related or non­Zika­virus­related; both are included 
in probability a. The probability of a laboratory marker of 
congenital infection being present is d, the diagnostic 
sensitivity.
The group with a negative PCR test result is a mixture 
of women who have an infection in pregnancy 
(proportion m), and women without an infection in 
pregnancy (proportion 1–m). In the absence of congenital 
infection there is still a possibility of an OPZRO, but 
now with probability b. The difference (a–b) therefore 
represents the pro portion of OPZROs among those with 
congenital infection that is causally attributable to 
maternal Zika virus infection. Congenital Zika syndrome 
can only occur in the presence of congenital infection.
We assumed that the vertical transmission rate, the 
risks of congenital Zika syndrome and of other adverse 
outcomes following congenital infection, and diagnostic 
sensitivity (ie, the parameters v, z, a, and d) vary by 
trimester and also between centres. The between­study 
variation in these parameters was captured by a random 
effects meta­analytical model (appendix p 3). We assumed 
that diagnostic sensitivity is the same, regardless of 
whether the clinical outcome is congenital Zika syn­
drome, OPZRO, or asymptomatic (figure): this was tested 
in a sensitivity analyses. The parameters b and m were 
assumed to vary only by centre, not by trimester, because 
they were not related to Zika virus.
To see how the data inform the model parameters, 
consider the data relating to the first trimester from 
the study by Pomar and colleagues16 (table 1). These 
six numbers estimate six probabilities as follows: the 
proportion with congenital Zika syndrome and positive 
laboratory markers (two of 68) is an estimate of the product 
vzd; the proportion with congenital Zika syndrome and 
negative laboratory markers (zero of 68) is an estimate of 
the product vz(1–d); the proportion with OPZROs and 
positive laboratory markers (five of 68) estimates v(1–z)ad; 
and the proportion with OPZROs and negative laboratory 
markers (nine of 68) could have Zika­virus­related or non­
Zika­virus­related OPZROs and therefore estimates a sum 
of products v(1–z)a(1–d) + (1–v)b. The same principle is 
followed for studies that do not report laboratory markers 
at all. For example, Hoen and colleagues17 reported 
congenital Zika syndrome in 13 of 189 patients after 
confirmed infection in trimester one; this estimates the 
product vz.
Turning to outcomes in PCR­negative women, the 
Spanish cohort reported seven of 60 patients with 
OPZROs after an infection in trimester three 
(unpublished data provided by AS­A): this is an 
estimate of m(v[1–z]a[1–d] + [1–v]b) + (1–m)b.
Although the relation between model parameters and 
data is complex, there are more items of data than model 
parameters, so they can all be estimated. The seven 
studies (table 1) each contribute directly or indirectly to 
every parameter; if any study is removed, all the estimates 
will change. Estimation was done by Bayesian Markov 
chain Monte Carlo methods. Details of the likelihood, 
model, prior distributions, model selection, conver gence 
checks, and software are available in the appendix 
(pp 3–11) along with the program code.
Sensitivity analyses
Sensitivity analyses assessed the robustness of 
conclusions to: (1) the degree of between­study variation 
in parameters v, z, a, and d; (2) the exclusion of each data 
source in turn; (3) the classification of fetal loss with 
undetermined clinical outcomes as congenital Zika 
syndrome or asymptomatic, rather than OPZRO; (4) the 
definition of congenital Zika syndrome being less than 
100% specific for congenital Zika virus infection; and 
(5) diagnostic sensi tivity being greater for congenital 
Zika syndrome outcomes than for OPZRO and 
asymptomatic.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study. The final decision to submit for 
publication was taken by CT as co­leader of the ZIKAction 
Vertical Transmission Work Package.
PCR-confirmed, by trimester of 
infection
PCR-negative, by trimester of 
infection
1 2 3 Not 
reported
1 2 3 Not 
reported
(Continued from previous page)
Conners et al (2018; PCR-negative patients reported as having a suspected MIP)20‡
LMCI present ·· ·· ·· 7 ·· ·· ·· 11
LMCI absent ·· ·· ·· 73 ·· ·· ·· 196
Total mother–child 
pairs
·· ·· ·· 80 ·· ·· ·· 207
Merriam et al (2020; PCR-negative patients reported as having a presumed MIP)21‡
CZS ·· ·· ·· 1 ·· ·· ·· 0
OPZRO ·· ·· ·· 1 + 1† ·· ·· ·· 6 + 1†
No symptoms ·· ·· ·· 13 ·· ·· ·· 47
Total mother–child 
pairs
·· ·· ·· 16 ·· ·· ·· 54
CZS=congenital Zika syndrome. MIP=maternal infection in pregnancy. LMCI=laboratory markers of congenital 
infection. OPZRO=other potentially Zika-virus-related outcome. *These unpublished data were provided by author 
AS-A. The protocol was published previously.19,22 †Fetal losses with undetermined or unreported clinical categorisation. 
‡For proportions of patients with confirmed or suspected infection in each trimester see the appendix (p 4).
Table 1: The number of mother–child pairs reported in each analysed study by clinical outcome, presence 
of laboratory marker of congenital infection, and MIP status
See Online for appendix
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Results
We report fetal and newborn outcomes for 1602 mother–
child pairs: 40 with congenital Zika syndrome, 181 with 
OPZROs, 1094 who were asymptomatic, and 287 who were 
unclassified. In our preferred model, selected on the basis 
of goodness­of­fit statistics and parsimony (appendix p 6), 
the estimated mean vertical transmission rate decreases 
from 47% (95% credible interval 26–76) for maternal 
infections in trimester one, to 28% (15–46) in trimester 
two, and 25% (13–47) in trimester three (table 2). The risk 
of congenital Zika syndrome conditional on congenital 
infection also decreased from 19% (8–37) in trimester one 
to 11% (5–25) in trimester two and 3% (0–12) in trimester 
three. The absolute risk of congenital Zika syndrome in 
women infected in pregnancy (the product of these 
two parameters) was 9% (4–17), 3% (1–7), and 1% (0–3) in 
the first, second, and third trimesters, respectively. 
Diagnostic sensitivity for congenital infection was esti­
mated to be 42% (18–72) after infections in trimester one, 
but was nearly twice that in trimesters two and three 
(table 2).
The average rate of OPZROs in infants with conge­
nital infection but without congenital Zika syndrome 
(para meter a in the figure) is approximately constant 
over the three trimesters (table 2). The overall rate of 
adverse outcomes, including congenital Zika syndrome, 
in those with a maternal infection in pregnancy is 24% 
(95% credible interval 14–37) in trimester one, 
14% (8–23) in trimester two, and 11% (5–20) in trimester 
three (table 2). Estimated rates of adverse outcomes 
unrelated to congenital infection (b in the figure) range 
from 1% (0–4) to 17% (4–33; table 3), and average 11%. 
Subtracting this from the overall rate of adverse 
outcomes in congenital infection, we obtained approxi­
mate estimates of the risks of adverse outcomes other 
than congenital Zika syndrome that can be attributed to 
Zika virus in pregnancy. The results of this subtraction 
(13%, 3%, and 0% in trimesters one, two, and three, 
respectively) suggest that most adverse outcomes 
attributable to Zika virus are within the definition of 
symptoms consistent with congenital Zika syndrome.
The estimated proportion of women with maternal 
infection in pregnancy in the PCR­negative comparison 
groups was 12% in Brasil and colleagues’ study;15 2% in 
the Spanish cohort, in which this (IgG­positive, PRNT 
non­negative) group were described as having a probable 
infection;19 26% in Merriam and colleagues’ study21 (IgM­
positive patients reported as having a presumed infection); 
and 52% in Conners and colleagues’ study20 (IgM­positive 
patients reported as having a suspected infection). These 
estimates have wide 95% credible intervals (table 3).
The sensitivity analyses establish that the general 
pattern of results in the base­case model is robust 
against a wide range of alternative assumptions (table 4). 
Estimated risks of congenital Zika syndrome are some­
what sensitive to the assumed level of between­study 
variation, with estimates from models that allow a little 
less (a factor of 1·5) or a little more (a factor of 3·0) 
variation by factors of 1·15 to 1·35 above and 
below the base­case estimates. Classification of fetal 
losses with undetermined clinical outcome as congenital 
Zika syndrome rather than OPZRO almost doubles 
Figure: Data generation process, showing the links between the observed data and the unobserved model parameters
OPZRO=other potentially Zika-virus-related outcome.
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the congenital Zika syndrome rate in trimester one. 
Removal of each study in turn generated a series of 
estimates of the congenital Zika syndrome rate in 
trimester one that varied from 7% to 11% (base case 9%) 
but did not affect the overall pattern of results. 
However, removal of the study by Pomar and colleagues16 
substantially reduced diagnostic sensitivity in trimesters 
one and two; in this study, a high proportion of con­
genital infection was diagnosed by PCR testing of 
placental samples.
If the diagnostic sensitivity is lower for OPZROs 
and asymptomatic outcomes than for congenital Zika 
syndrome, even by a log odds ratio of 2, the predicted 
vertical transmission rate is increased by a factor of no 
more than 1·1, and the rate of congenital Zika syndrome 
conditional on vertical transmission is decreased by the 
same amount, so the overall effect on the predicted rate 
of congenital Zika syndrome is negligible. The results 
were more sensitive to the assumption that our definition 
of congenital Zika syndrome is 100% specific for 
congenital Zika virus: lowering the positive predictive 
value to 80% or 60% had the effect of decreasing both the 
estimated congenital Zika syndrome rate conditional on 
vertical transmission and the absolute congenital Zika 
syndrome rate by the same proportion. Decreasing the 
positive predictive value also results in an increase in 
the estimated vertical transmission rate, especially in 
trimester one, whereas estimated diagnostic sensitivity is 
decreased.
Discussion
Previous studies15–21 have reported rates of adverse 
outcomes of congenital Zika virus infection between 
7% and 46%, and vertical transmission rates between 
9% and 35%, but these rates are substantially under­
estimated because they take no account of the low 
diagnostic sensitivity of tests for fetal infection shown by 
our model (42% in the first trimester). Taking this into 
account, we found that vertical transmission rates 
declined with trimester of maternal infection, as did 
rates of congenital Zika syndrome. Following a 
Zika virus infection in pregnancy, the incidence of 
adverse outcomes, including congenital Zika syndrome, 
likely to be caused by maternal Zika virus infection was 
substantially higher in trimester one than in trimester two 
or three. Given the likelihood of error in the reported 
trimester of infection, it might be that all Zika­virus­
related outcomes are due to infection in trimester one. 
From our results, we can deduce that, following an 
infection in pregnancy, about 35% of adverse outcomes 
are directly or indirectly attributable to maternal infection 
(or 55% after infections in trimester one), which is 
consistent with Pomar and colleagues’ estimate of 47% of 
adverse outcomes being due to Zika virus following 
diagnosed congenital infection.16
Our findings, based on only seven studies done in 
diverse settings, many reporting incomplete data, are no 
more than preliminary. However, the findings are 
consistent with previous reports, and robust against 
challenge from a wide range of sensitivity analyses.
Latent class models could be extended to include 
a wider array of outcome categories, potential effect 
modifiers such as previous flavivirus infections,24,25 and 
extended to individual patient data. Information on the 
analytical sensitivity of diagnostic tests could also be 
incorporated. ON the basis of our sensitivity analyses, 
tests on amniotic fluid and perhaps placental samples 
should be distinguished from tests on neonatal samples. 
With adequate data, the model we used (figure) can be 
modified to distinguish outcomes that are the result of 
congenital infection, such as congenital Zika syndrome, 
and out comes such as fetal loss, stillbirth, or prematurity, 
which could be the result of congenital infection or of 
maternal Zika virus infection in the absence of 
congenital infection, as is seen with other infections in 











Probability of vertical transmission given 
maternal infection in pregnancy
47% (26 to 76) 28% (15 to 46) 25% (13 to 47)
Probability of congenital Zika syndrome given 
congenital infection
19% (8 to 37) 11% (5 to 25) 3% (0 to 12)
Probability of congenital Zika syndrome given 
maternal infection in pregnancy
9% (4 to 17) 3% (1 to 7) 1% (0 to 3)
Diagnostic sensitivity 42% (18 to 72) 85% (51 to 99) 80% (42 to 99)
Probability of OPZRO given congenital infection 42% (22 to 65) 46% (27 to 64) 43% (23 to 66)
Probability of any adverse outcome given 
maternal infection in pregnancy
24% (14 to 37) 14% (8 to 23) 11% (5 to 20)
Probability of any adverse outcome 
attributable to congenital infection given 
maternal infection in pregnancy
13% (2 to 27) 3% (–5 to 14) 0% (–7 to 11)
Data are median (95% credible interval). OPZRO=other potentially Zika-virus-related outcome.
Table 2: Target parameters: posterior summaries from the preferred model
Proportion of 
neonates with 
adverse outcomes in 
the absence of 





with Zika virus 
infection in 
pregnancy
Pomar et al (2018)16 9% (2–15) ··
Nogueira et al (2018)18 17% (4–33) ··
Hoen et al (2018)17 1% (0–4) ··
Rodó et al (2019)19 13% (9–19) 2% (0–16)
Brasil et al (2016)15 13% (2–29) 12% (1–49)
Merriam et al (2020)21 11% (2–22) 26% (1–91)
Conners et al (2017)20 ·· 52% (23–94)
Data are median (95% credible interval).
Table 3: Study-specific parameters: posterior summaries from the 
preferred model
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Results are awaited from several large, multicentre cohort 
studies of Zika virus in pregnancy (eg, NCT02856984, and 
ZIKAlliance, ZIKAction, and ZikaPLAN studies). Statistical 
plans for pooled data analysis have been, or are being, 
prepared by the Zika Virus Individual Participant Data 
Meta­analysis Consortium,29 the European Commission 
consortia, and the Brazilian Ministry of Health. In the 
absence of accurate diagnostics for congenital infection, 
inference regarding the causal effects of Zika virus in 
pregnancy can only be made by comparing outcomes in 
women with and without infection in pregnancy, but—as 
we have seen—the only available control groups are 
mixtures of both infected and uninfected women. In one 
analysis plan,29 the intention is to regress the relative risk of 
adverse outcomes in PCR­positive women relative to PCR­
negative women against estimates of test sensitivity and 
specificity. However, it is not clear that meta­regression 
would adjust for test inaccuracy: lack of either sensitivity or 
specificity will bias relative risks towards a null effect. 
Furthermore, the proportion of true and false positive 
diagnoses of maternal infection, which is our study­specific 
para meter m, is far more sensitive to the absolute and 
relative incidence of Zika virus and cross­reacting 
flaviviruses, than to sensitivity and specificity.
By contrast, Bayesian latent class analysis estimates 
the study­specific mixing proportions and delivers 
estimates of parameters that are crucial for scientific 
understanding and causal inference: namely the vertical 
transmission rate and rates of adverse outcomes 
attributable to Zika virus.
The models we have used have several limitations. We 
assumed that vertical trans mission rates, congenital Zika 
syndrome and OPZRO rates conditional on vertical 
transmission, and diagnostic sensitivity varied randomly 
across studies. The estimated means are only averages 
over the studies included. We adopted informative 
priors for between­study variation, because there were 
insufficient data to estimate the extent of variation in all 
four parameters (v, z, a, and d), although sensitivity 
analyses suggest that results are robust to reasonable 
changes in previous assumptions. Analyses suggested a 
high level of between­study variation in the target 
parameters (appendix p 6), which is unexplained. The 
small quantity of data prevented many extensions 
and elaborations that would be required in a definitive 
analysis.
Conclusions are limited to outcomes manifested by the 
end of the perinatal period and therefore do not account 
Vertical transmission 
rate after maternal 
infection in pregnancy





Diagnostic sensitivity CZS after maternal 
infection in 
pregnancy
CZS or OPZRO after 
maternal infection 
in pregnancy
T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3 T1 T2 T3
Base case 46% 28% 25% 19% 11% 3% 42% 46% 43% 42% 85% 80% 9% 3% 1% 24% 14% 11%
Between-trial variation: base case assumes that 95% of study-specific outcomes are within a factor of 2 above or below the median
Factor of 1·0: fixed effect 28% 23% 22% 22% 10% 3% 33% 31% 33% 62% 96% 89% 6% 2% 1% 14% 9% 8%
Factor of 1·5: random effect 48% 26% 26% 22% 15% 4% 40% 44% 42% 45% 88% 82% 8% 3% 1% 22% 13% 10%
Factor of 3·0: random effect 48% 29% 26% 20% 12% 4% 43% 47% 44% 39% 82% 78% 9% 3% 1% 26% 15% 12%
Factor of 1200: random effect 46% 31% 26% 36% 24% 8% 45% 49% 46% 35% 78% 75% 16% 7% 2% 30% 19% 13%
Classification of fetal loss outcomes with undetermined status as OPZRO, CZS, or asymptomatic: base case classifies them as OPZRO
CZS 45% 28% 25% 35% 16% 8% 38% 46% 42% 45% 78% 79% 16% 5% 2% 27% 15% 12%
Asymptomatic 49% 26% 24% 18% 11% 3% 29% 43% 40% 38% 87% 80% 9% 3% 1% 20% 13% 10%
Removal of data, one study at a time, and removal of all data
Pomar et al (2018)16 48% 28% 21% 24% 12% 5% 46% 39% 56% 27% 64% 73% 11% 3% 1% 27% 13% 12%
Nogueira et al (2018)18 43% 24% 22% 22% 14% 4% 45% 51% 39% 40% 83% 74% 9% 3% 1% 24% 14% 9%
Hoen et al (2018)17 47% 37% 30% 14% 10% 2% 47% 52% 46% 42% 75% 75% 7% 4% 1% 25% 21% 14%
Rodó et al (2019)19 44% 31% 27% 16% 8% 0% 41% 42% 40% 49% 84% 80% 7% 2% 1% 22% 14% 11%
Brasil et al (2016)15 39% 21% 21% 21% 11% 5% 34% 36% 41% 43% 90% 81% 8% 2% 1% 18% 9% 9%
Merriam et al (2020)21 48% 29% 26% 20% 11% 3% 43% 47% 43% 41% 84% 79% 9% 3% 1% 26% 15% 12%
Conners et al (2017)20 51% 33% 29% 17% 9% 3% 40% 42% 42% 46% 85% 82% 8% 3% 1% 25% 16% 13%
All data removed 50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 50% 18% 18% 18% 34% 34% 34%
Lower diagnostic sensitivity with OPZRO and asymptomatic outcomes relative to CZS: base case has equal diagnostic sensitivity
Log odds ratio 0·5 51% 30% 26% 17% 10% 3% 39% 44% 42% 49% 85% 84% 8% 3% 1% 25% 15% 12%
Definition of CZS not 100% specific for congenital Zika virus: base-case positive predictive value is 100%
Positive predictive value 80% 51% 28% 25% 14% 8% 2% 42% 46% 44% 36% 82% 78% 7% 2% 1% 25% 14% 11%
Positive predictive value 60% 64% 32% 27% 10% 6% 2% 36% 45% 44% 24% 73% 74% 6% 2% 0% 27% 15% 12%
Data are posterior median percent. CZS=congenital Zika syndrome. OPZRO=other potentially Zika-virus-related outcome. T1=trimester 1. T2=trimester 2. T3=trimester 3.
Table 4: Sensitivity analyses for each outcome by trimester of maternal infection
For more on ZIKAlliance studies 
see https://zikalliance.tghn.org/
For more on ZIKAction studies 
see https://zikaction.org/
For more on ZikaPLAN studies 
see https://zikaplan.tghn.org/
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for outcomes that resolve, and other outcomes that develop 
subsequently.30 The most important limitations arise 
from uncertainties about integrity of data collection and 
recruitment. Although all the studies included seemed to 
be consistent with prospective ascertainment, this can be 
difficult to implement, and there is a danger of selective 
recruitment of symptomatic cases, perhaps especially in 
retrospectively reconstructed or surveillance cohorts.19–21 
This is more easily avoided in prospective studies in which 
every pregnant woman is recruited. Selective inclusion of 
congenital Zika syndrome detected on prenatal ultra­
sonography might have occurred. In studies that include 
both a PCR­positive and PCR­negative comparison 
group,15,19 if recruitment was truly prospective, the dis­
tribution of cases across trimesters should be the same in 
both groups. The data from table 1 suggest that these 
studies might not have passed this test, and it is hard to 
rule out the possibility that neonates with more severe 
outcomes were tested more intensively. Our sensitivity 
analyses showed that higher diagnostic sensitivity with 
severe outcomes has little effect on estimates of vertical 
transmission or adverse outcome rates, but this does not 
address the potential for biases due to selective recruitment 
of patients with more severe outcomes.
The ZIKAlliance, ZIKAction, and ZikaPLAN studies 
are standard prospective designs offering recruitment to 
all eligible pregnant women. It is possible that these 
studies will generate superior data, especially on control 
groups in whom maternal infection can be ruled out 
with a high level of certainty. These studies will deliver 
better data on the risk of adverse outcomes in the 
absence of maternal infection and will help to distinguish 
the causal effects of congenital Zika virus infection from 
indirect effects of maternal Zika virus infection.
The high transmission rate in trimester one, an unusual 
finding with congenital infections, although not unique,7 
is supported by experimental evidence. The haematogenic 
route for Zika virus vertical transmission relies on 
three possible entry sites to access fetal circulation: (1) the 
maternal decidual tissues and the juxtaposed fetal extra­
villous trophoblasts; (2) the syncytiotrophoblast layer 
covering the villous trophoblast; and (3) the amnio­
chorionic membrane surrounding the fetus. Each has 
been investigated in vitro to define when the placenta is 
most permissive to infection.
Villous and decidual explants of the first trimester are 
highly susceptible to Zika virus,31,32 as evidenced by a 
wide variety of virus­positive cells of both maternal and 
fetal origin, namely extravillous trophoblasts, prolife­
rating trophoblasts, glandular cells, and decidual cells. 
Although decidual tissues maintain their susceptibility to 
Zika virus throughout pregnancy,33,34 chorionic villi 
gradually decrease their permissivity after the first 
trimester.33 Primary trophoblast cells and villous explants 
derived from the second and third trimesters are either 
resistant or poorly susceptible to Zika virus, because 
of the release of type III interferon, IFNλ1, by the 
syncytio trophoblast, acting both at a paracrine and auto­
crine level.35,36 More over, Sheridan and colleagues37 
showed that trophoblasts derived from embryonic stem 
cells that are analogous to the primitive placental cells at 
the time of implantation support a quick and productive 
replication of the virus, whereas primary trophoblasts 
and syncytiotrophoblasts from term placentas are resis­
tant to Zika virus infection. Regarding the amnio­
chorionic membrane, amniotic epithelial cells from mid­
gestation generate higher infectious titres than the ones 
obtained from late­gestation placentas.32 These findings 
suggest a decreasing susceptibility of con stituents of the 
placental barrier over the course of gestation, consistent 
with the vertical transmission risks we have described.
The causes of the between­study variation in vertical 
transmission rates and sequelae rates remain to be 
identified. Although WHO has produced standardised 
protocols for studies of Zika virus in pregnancy,38 studies 
have used a variety of clinical definitions, diagnostic tests, 
and testing schedules. Latent class analysis can remove the 
variation engendered by these incidental factors, allowing 
investigators to focus on the real causes of between­centre 
variation. An individual patient data analysis of datasets 
with harmonised definitions, protocols, and diagnostics is 
the ideal, but latent class analysis will still be required to 
handle diagnostic test inaccuracy. The objective now is to 
build a larger and more detailed evidence base for a more 
comprehensive analysis.
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